Chronic myelogenous leukemia (CML) cells treated with BCR-ABL inhibitors resumed proliferation immediately after drug removal, whereas cells treated with 32 could not proliferate and eventually underwent cell death under the same conditions. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.